Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs
暂无分享,去创建一个
Feixiong Cheng | Zengrui Wu | Weihua Li | Yun Tang | Guixia Liu | F. Cheng | Weihua Li | Zengrui Wu | Guixia Liu | Yun Tang | Jianwen Liu | Jie Li | Jianwen Liu | Kecheng Lei | Jie Li | Kecheng Lei
[1] Tongbin Li,et al. miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..
[2] Yiwei Li,et al. Regulating miRNA by natural agents as a new strategy for cancer treatment. , 2013, Current drug targets.
[3] J. Hescheler,et al. Modulation of miRNAs by natural agents: Nature’s way of dealing with cancer , 2015 .
[4] Jie Shen,et al. Adverse Drug Events: Database Construction and in Silico Prediction , 2013, J. Chem. Inf. Model..
[5] Jianyi Li,et al. Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[6] Xia Li,et al. SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression , 2013, Bioinform..
[7] Ana Kozomara,et al. miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..
[8] Kathryn A. O’Donnell,et al. c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.
[9] Longhua Chen,et al. MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. , 2015, International journal of radiation oncology, biology, physics.
[10] A. Alizadeh,et al. MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer. , 2016, Life sciences.
[11] Chi-Ying F. Huang,et al. miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..
[12] Trey Ideker,et al. Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..
[13] Y. Wang,et al. OCT4 as a target of miR-34a stimulates p63 but inhibits p53 to promote human cell transformation , 2014, Cell Death and Disease.
[14] M. Disney,et al. Small molecule chemical probes of microRNA function. , 2015, Current opinion in chemical biology.
[15] A. Hatzigeorgiou,et al. TarBase: A comprehensive database of experimentally supported animal microRNA targets. , 2005, RNA.
[16] E. Olson,et al. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles , 2012, Nature Reviews Drug Discovery.
[17] Jie Li,et al. Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..
[18] Aleix Prat Aparicio. Comprehensive molecular portraits of human breast tumours , 2012 .
[19] Klaus Pantel,et al. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients , 2012, Breast Cancer Research and Treatment.
[20] Howard L McLeod,et al. Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.
[21] Jie Shen,et al. Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). , 2013, Molecular bioSystems.
[22] Jasjit K. Banwait,et al. Contribution of bioinformatics prediction in microRNA-based cancer therapeutics. , 2015, Advanced drug delivery reviews.
[23] C. Croce,et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] Jeannette Bigler,et al. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.
[25] George A Calin,et al. Small molecule compounds targeting miRNAs for cancer therapy. , 2015, Advanced drug delivery reviews.
[26] Noam Shomron,et al. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. , 2011, Trends in molecular medicine.
[27] A. Gavin,et al. SnapShot: Protein-Protein Interaction Networks , 2011, Cell.
[28] G. Schratt,et al. microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases , 2009, Neuroscience Letters.
[29] Andrey Golubov,et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.
[30] Stefano Volinia,et al. Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.
[31] Jing Wang,et al. Psmir: a database of potential associations between small molecules and miRNAs , 2016, Scientific Reports.
[32] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[33] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[34] Jie Li,et al. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning , 2016, Briefings Bioinform..
[35] Russell Bowler,et al. The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations , 2014, Nucleic acids research.
[36] M. Nakajima,et al. microRNAs as mediators of drug toxicity. , 2013, Annual review of pharmacology and toxicology.
[37] M. Ingelman-Sundberg,et al. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. , 2009, Pharmacogenomics.
[38] C. Klinge. miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets , 2015, Molecular and Cellular Endocrinology.
[39] Alexander Deiters,et al. Small Molecule Modifiers of the microRNA and RNA Interference Pathway , 2010, The AAPS Journal.
[40] Qing Wu,et al. miREnvironment Database: providing a bridge for microRNAs, environmental factors and phenotypes , 2011, Bioinform..
[41] Most Mauluda Akhtar,et al. Bioinformatic tools for microRNA dissection , 2015, Nucleic acids research.
[42] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[43] F. Yu,et al. MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival , 2012, PloS one.
[44] C E Lipscomb,et al. Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.
[45] Noam Shomron,et al. MicroRNAs and pharmacogenomics. , 2010, Pharmacogenomics.
[46] S. Zhong,et al. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. , 2013, Gene.
[47] Jie Li,et al. Computational prediction of microRNA networks incorporating environmental toxicity and disease etiology , 2014, Scientific Reports.
[48] Jing Wang,et al. Identifying novel associations between small molecules and miRNAs based on integrated molecular networks , 2015, Bioinform..
[49] Gary D. Bader,et al. An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.
[50] M. Eileen Dolan,et al. Cancer pharmacogenomics: strategies and challenges , 2012, Nature Reviews Genetics.
[51] Huixiao Hong,et al. microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. , 2015, Biomarkers in medicine.
[52] Q. Cui,et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB mediated transcription of microRNAs , 2012, Oncogene.
[53] Urs A Meyer,et al. Omics and drug response. , 2013, Annual review of pharmacology and toxicology.
[54] Feixiong Cheng,et al. Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science. , 2015, Biomarkers in medicine.
[55] David L. Wheeler,et al. GenBank , 2015, Nucleic Acids Res..
[56] W. Gallagher,et al. miRNA dysregulation in breast cancer. , 2013, Cancer research.
[57] Yadi Zhou,et al. Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method , 2012, PloS one.